Hilleman Laboratories is committed to developing high impact, affordable vaccines for people in developing countries in an innovative and sustainable manner.

Hilleman Labs successfully completes Phase I/II Clinical Trial of its Heat

Date: 12/10/2017

Hilleman Labs achieves successful outcome of Phase I/II Clinical Trial of i

Date: 12/10/2017

Hilleman Laboratories receives Indo-Swedish grant for developing - Oral Cho

Date: 28/09/2017

Building Healthy Partnership

Date: 04/05/2017

Hilleman Laboratories signs MoU with NICED, ICMR to develop Shigella Vaccin

Date: 29/03/2017

Hilleman Laboratories awarded global patents for Oral Cholera Vaccine

Date: 10/01/2017

Nitya Sharma at Hilleman Labs and Amity University awarded the prestigious

Date: 22/12/2016

Sustained funding is difficult to get in India

Date: 11/10/2016

Hilleman Lab scouts for partners to launch rotavirus vaccine in India

Date: 29/09/2016

Hilleman Labs workshop on Nutrition and Immunity for Infant and Child Heal

Date: 21/09/2016

Hilleman Laboratories scientist Dr. Ankur Mutreja awarded prestigious - “

Date: 23/06/2016

Hilleman Laboratories advances two vaccines into clinical stage

Date: 27/04/2016

Hilleman Labs CEO, Dr. Davinder Gill, speaks with Wall Street Journal on th

Date: 28/03/2016

Hilleman Laboratories Announces Key Senior Leadership Appointment

Date: 08/03/2016

Wellcome Trust Delegates visit Hilleman Laboratories, India

Date: 05/02/2016